Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.03, Bloomberg Earnings reports.
Shares of Bellerophon Therapeutics (BLPH) traded up 2.65% on Friday, hitting $1.16. The stock had a trading volume of 186,718 shares. The firm’s market capitalization is $41.19 million. The company has a 50 day moving average of $1.32 and a 200-day moving average of $1.32. Bellerophon Therapeutics has a 12-month low of $0.43 and a 12-month high of $1.98.
Several equities research analysts have recently weighed in on the company. Zacks Investment Research upgraded Bellerophon Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price objective on the stock in a research note on Monday, August 14th. ValuEngine lowered Bellerophon Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 10th.
COPYRIGHT VIOLATION WARNING: “Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Announces Quarterly Earnings Results” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.com-unik.info/2017/08/19/bellerophon-therapeutics-inc-nasdaqblph-posts-quarterly-earnings-results-beats-estimates-by-0-03-eps-updated.html.
An institutional investor recently raised its position in Bellerophon Therapeutics stock. Vanguard Group Inc. boosted its stake in Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) by 52.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 612,641 shares of the biotechnology company’s stock after buying an additional 211,111 shares during the period. Vanguard Group Inc. owned about 1.86% of Bellerophon Therapeutics worth $821,000 as of its most recent SEC filing. 42.11% of the stock is currently owned by institutional investors.
Bellerophon Therapeutics Company Profile
Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.
What are top analysts saying about Bellerophon Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bellerophon Therapeutics Inc. and related companies.